骨粗鬆症治療薬の世界市場レポート 2025年

骨粗鬆症治療薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR3.1％で144億8,000万米ドルに成長します。予測期間の成長は、継続的な高齢化傾向、治療オプションの進歩、男性の骨の健康への注目の高まり、患者の教育とエンパワーメント、世界の医療政策と保険適用に起因すると考えられます。予測期間における主な動向としては、個別化医療へのアプローチ、併用療法の模索、骨折予防戦略の重視、新規創薬ターゲットへの研究開発投資、医薬品開発のための共同研究などが挙げられます。

骨粗鬆症の有病率の増加は、骨粗鬆症治療薬市場の成長を促進すると予想されます。骨粗鬆症は、骨密度や骨量の減少、骨質や骨構造の変化を特徴とする骨の疾患です。カルシウム摂取量が少ない人は、骨粗鬆症を発症するリスクが高いです。これらの骨粗鬆症治療薬は、骨密度を高め、骨折の可能性を減らす働きをします。例えば、2024年6月、オーストラリアの政府機関であるオーストラリア保健福祉研究所は、骨粗鬆症が2022年の死亡原因2,659人、人口10万人当たり10.2人の死亡に相当し、全死亡の1.4％を占めると報告しました。このように、骨粗鬆症の有病率の上昇が骨粗鬆症治療薬市場の成長を促進しています。

高齢化の進展は、当面の骨粗鬆症治療薬市場成長の重要な促進要因になると予想されます。高齢化とは、主に出生率の低下と平均寿命の延長の影響を受けて、人口の中央年齢が上昇することを指します。骨粗鬆症のリスクは、骨密度の自然な低下により加齢とともに高まることが知られています。高齢者人口の拡大は、骨粗鬆症治療薬の需要拡大に寄与しています。例えば、スイスに本部を置く政府間機関である世界保健機関（WHO）の2022年のデータによると、60歳以上の世界人口は10億人から14億人に増加しました。2050年の予測では、世界の60歳以上の人口は倍増し、21億人に達すると予想されています。したがって、高齢化人口の増加が骨粗鬆症治療薬市場の成長を促進する重要な要因として浮上しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界骨粗鬆症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の骨粗鬆症治療薬市場：成長率分析
• 世界の骨粗鬆症治療薬市場の実績：規模と成長, 2019-2024
• 世界の骨粗鬆症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界骨粗鬆症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の骨粗鬆症治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビスフォスフォネート
• 選択的エストロゲン受容体モジュレーター（SERM）
• RANKリガンド阻害剤
• 世界の骨粗鬆症治療薬市場管理による、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射可能
• 世界の骨粗鬆症治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小売薬局
• 病院薬局
• オンライン販売
• 世界の骨粗鬆症治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 原発性骨粗鬆症
• 続発性骨粗鬆症
• 世界の骨粗鬆症治療薬市場ビスフォスフォネートの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アレンドロネート
• リセドロネート
• イバンドロネート
• ゾレドロン酸
• 世界の骨粗鬆症治療薬市場選択的エストロゲン受容体モジュレーター（SERM）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ラロキシフェン
• バゼドキシフェン
• 世界の骨粗鬆症治療薬市場RANKリガンド阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• デノスマブ

第7章 地域別・国別分析

• 世界の骨粗鬆症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の骨粗鬆症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 骨粗鬆症治療薬市場：競合情勢
• 骨粗鬆症治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline PLC
• Eli Lilly and Company
• Amgen Inc.
• Novo Nordisk A/S
• Asahi Kasei Pharma Corporation
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd
• Mylan N.V.
• Daiichi Sankyo Company Limited
• Sun Pharmaceutical Industries Ltd.
• Ipsen
• Kyowa Kirin Co Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Recordati S.p.A.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 骨粗鬆症治療薬市場2029：新たな機会を提供する国
• 骨粗鬆症治療薬市場2029：新たな機会を提供するセグメント
• 骨粗鬆症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Osteoporosis drugs are medications designed to increase bone mineral density, reducing the risk of fractures. They are used both in the treatment and prevention of fractures, aiming to strengthen bones and prevent bone loss associated with osteoporosis.

The primary categories of osteoporosis drugs comprise bisphosphonates, selective estrogen receptor modulators (SERMS), and rank ligand inhibitors. Bisphosphonates are a class of medications aimed at addressing bone conditions such as osteopenia or osteoporosis, both characterized by fragile or thin bones susceptible to fractures. These drugs are available in oral and intravenous forms, distributed through diverse channels such as retail pharmacies, hospital dispensaries, and online sales platforms. They find application in treating both primary and secondary osteoporosis.

The osteoporosis drugs market research report is one of a series of new reports from The Business Research Company that provides osteoporosis drugs market statistics, including osteoporosis drugs industry global market size, regional shares, competitors with a osteoporosis drugs market share, detailed osteoporosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis drugs industry. This osteoporosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The osteoporosis drugs market size has grown steadily in recent years. It will grow from $12.33 billion in 2024 to $12.8 billion in 2025 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to aging population, increased awareness and diagnosis, lifestyle factors, government initiatives and healthcare policies.

The osteoporosis drugs market size is expected to see steady growth in the next few years. It will grow to $14.48 billion in 2029 at a compound annual growth rate (CAGR) of 3.1%. The growth in the forecast period can be attributed to continued aging population trends, advancements in treatment options, increased focus on men's bone health, patient education and empowerment, global health policies and insurance coverage. Major trends in the forecast period include personalized medicine approaches, exploration of combination therapies, focus on fracture prevention strategies, R&D investment in novel drug targets, collaborations for drug development.

An increase in the prevalence of osteoporosis is anticipated to drive the growth of the osteoporosis drug market. Osteoporosis is a bone condition characterized by a decrease in bone mineral density and mass or changes in bone quality and structure. Individuals with low calcium intake are at a higher risk of developing osteoporosis. These osteoporosis medications work to enhance bone mineral density and reduce the likelihood of fractures. For example, in June 2024, the Australian Institute of Health and Welfare, an Australian government agency, reported that osteoporosis was responsible for 2,659 deaths in 2022, which equates to 10.2 deaths per 100,000 people, accounting for 1.4% of all deaths. Thus, the rising prevalence of osteoporosis is propelling the growth of the osteoporosis drug market.

The rising aging population is anticipated to be a significant driver for the growth of the osteoporosis drug market in the foreseeable future. The aging population refers to an increase in the median age of a population, primarily influenced by declining fertility rates and prolonged life expectancy. Osteoporosis risk is known to escalate with age due to the natural decline in bone density. The expanding demographic of elderly individuals contributes to a growing demand for osteoporosis medications. For example, in 2022, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that the global population aged 60 years and over increased from 1 billion to 1.4 billion. Projections for 2050 anticipate a doubling of the world's population of individuals aged 60 years and older to reach 2.1 billion. Hence, the increasing aging population emerges as a key factor driving the growth of the osteoporosis drug market.

Key players in the osteoporosis drugs industry are driving forward with innovative approaches to address this market. An example of this progress is seen in Apotex Inc., a Canadian pharmaceutical giant, which introduced the Teriparatide Injectable for Osteoporosis Treatment in November 2023. This pre-filled pen, containing 250 mcg/mL, facilitates 28 daily doses of 20 mcg each, specifically designed for single-patient usage. This offering aims to provide affordable access to much-needed treatment for patients dealing with osteoporosis.

Major players in the osteoporosis drug market are strategically leveraging partnerships to ensure dependable services for their clientele. A case in point is the December 2022 collaboration between Chugai Pharmaceutical Co. Ltd., a Japanese pharmaceutical company, and Towa Pharmaceutical Co. Ltd., a Japan-based manufacturer specializing in generic drug development. This alliance facilitated the introduction of Edirol Tablet for osteoporosis treatment. Chugai's production of Edirol tablets, supplied to Towa, showcases this active vitamin D3 derivative's efficacy in enhancing calcium and bone metabolism. This joint effort significantly contributes to diversifying treatment options available in the osteoporosis drug market, addressing the needs of individuals dealing with this condition.

In May 2023, Abiogen Pharma S.p.A., an Italy-based pharmaceutical company that offers various pharmaceutical products, acquired EffRx Pharmaceuticals for an undisclosed amount. With this acquisition, Abiogen Pharma intends to bolster its international presence, enhance its product offerings in bone health, leverage synergies for more effective drug development, and concentrate on rare diseases. EffRx Pharmaceuticals, a Switzerland-based company, specializes in creating innovative treatments for osteoporosis, aiming to improve bone density and minimize fracture risk. Their therapies focus on specific biological pathways to promote bone health in patients suffering from this condition.

Major companies operating in the osteoporosis drugs market include Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Pharma Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd, Mylan N.V., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Ipsen, Kyowa Kirin Co Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Recordati S.p.A., Cadila Healthcare Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Theramex, Radius Health Inc., Strides Pharma Science Limited, Apotex Inc.

North America was the largest region in the osteoporosis market in 2024. The regions covered in the osteoporosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the osteoporosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteoporosis drugs market consists of sales of antiresorptive drugs and anabolic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteoporosis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteoporosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osteoporosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteoporosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Bisphosphonates; Selective Estrogen Receptor Modulators (SERMs); RANK Ligand Inhibitors
• 2) By Administration: Oral; Injectable
• 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Sales
• 4) By Application: Primary Osteoporosis; Secondary Osteoporosis
• Subsegments:
• 1) By Bisphosphonates: Alendronate; Risedronate; Ibandronate; Zoledronic Acid
• 2) By Selective Estrogen Receptor Modulators (SERMs): Raloxifene; Bazedoxifene
• 3) By RANK Ligand Inhibitors: Denosumab
• Companies Mentioned: Pfizer Inc.; F. Hoffmann La Roche Ltd.; Merck & Co Inc.; Novartis AG; Bristol Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Osteoporosis Drugs Market Characteristics

3. Osteoporosis Drugs Market Trends And Strategies

4. Osteoporosis Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Osteoporosis Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Osteoporosis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Osteoporosis Drugs Market Growth Rate Analysis
• 5.4. Global Osteoporosis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Osteoporosis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Osteoporosis Drugs Total Addressable Market (TAM)

6. Osteoporosis Drugs Market Segmentation

• 6.1. Global Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bisphosphonates
• Selective Estrogen Receptor Modulators (SERMs)
• RANK Ligand Inhibitors
• 6.2. Global Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.3. Global Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Hospital Pharmacies
• Online Sales
• 6.4. Global Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Osteoporosis
• Secondary Osteoporosis
• 6.5. Global Osteoporosis Drugs Market, Sub-Segmentation Of Bisphosphonates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alendronate
• Risedronate
• Ibandronate
• Zoledronic Acid
• 6.6. Global Osteoporosis Drugs Market, Sub-Segmentation Of Selective Estrogen Receptor Modulators (SERMs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Raloxifene
• Bazedoxifene
• 6.7. Global Osteoporosis Drugs Market, Sub-Segmentation Of RANK Ligand Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Denosumab

7. Osteoporosis Drugs Market Regional And Country Analysis

• 7.1. Global Osteoporosis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Osteoporosis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Osteoporosis Drugs Market

• 8.1. Asia-Pacific Osteoporosis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Osteoporosis Drugs Market

• 9.1. China Osteoporosis Drugs Market Overview
• 9.2. China Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Osteoporosis Drugs Market

• 10.1. India Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Osteoporosis Drugs Market

• 11.1. Japan Osteoporosis Drugs Market Overview
• 11.2. Japan Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Osteoporosis Drugs Market

• 12.1. Australia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Osteoporosis Drugs Market

• 13.1. Indonesia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Osteoporosis Drugs Market

• 14.1. South Korea Osteoporosis Drugs Market Overview
• 14.2. South Korea Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Osteoporosis Drugs Market

• 15.1. Western Europe Osteoporosis Drugs Market Overview
• 15.2. Western Europe Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Osteoporosis Drugs Market

• 16.1. UK Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Osteoporosis Drugs Market

• 17.1. Germany Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Osteoporosis Drugs Market

• 18.1. France Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Osteoporosis Drugs Market

• 19.1. Italy Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Osteoporosis Drugs Market

• 20.1. Spain Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Osteoporosis Drugs Market

• 21.1. Eastern Europe Osteoporosis Drugs Market Overview
• 21.2. Eastern Europe Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Osteoporosis Drugs Market

• 22.1. Russia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Osteoporosis Drugs Market

• 23.1. North America Osteoporosis Drugs Market Overview
• 23.2. North America Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Osteoporosis Drugs Market

• 24.1. USA Osteoporosis Drugs Market Overview
• 24.2. USA Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Osteoporosis Drugs Market

• 25.1. Canada Osteoporosis Drugs Market Overview
• 25.2. Canada Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Osteoporosis Drugs Market

• 26.1. South America Osteoporosis Drugs Market Overview
• 26.2. South America Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Osteoporosis Drugs Market

• 27.1. Brazil Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Osteoporosis Drugs Market

• 28.1. Middle East Osteoporosis Drugs Market Overview
• 28.2. Middle East Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Osteoporosis Drugs Market

• 29.1. Africa Osteoporosis Drugs Market Overview
• 29.2. Africa Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Osteoporosis Drugs Market Competitive Landscape And Company Profiles

• 30.1. Osteoporosis Drugs Market Competitive Landscape
• 30.2. Osteoporosis Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Osteoporosis Drugs Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline PLC
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. Novo Nordisk A/S
• 31.5. Asahi Kasei Pharma Corporation
• 31.6. Viatris Inc.
• 31.7. Teva Pharmaceutical Industries Ltd
• 31.8. Mylan N.V.
• 31.9. Daiichi Sankyo Company Limited
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Ipsen
• 31.12. Kyowa Kirin Co Ltd.
• 31.13. Dr. Reddy's Laboratories Ltd.
• 31.14. Cipla Limited
• 31.15. Recordati S.p.A.

32. Global Osteoporosis Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Osteoporosis Drugs Market

34. Recent Developments In The Osteoporosis Drugs Market

35. Osteoporosis Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Osteoporosis Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Osteoporosis Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Osteoporosis Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer